Cutler Group’s OncoMed Pharmaceuticals, Inc. OMED Stock Holding History

Cutler Group’s Portfolio OMED Stock Details OMED Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q2	–	Sell	-856	Closed	-$2K	–	5398
2018 Q1	$2K	Hold	856	–	–	﹤0.01%	3941
2017 Q4	$3K	Hold	856	–	–	﹤0.01%	4080
2017 Q3	$3K	Sell	856 -4,680	-85%	-$19K	﹤0.01%	4983
2017 Q2	$18K	Sell	5,536 -539	-9%	-$2.24K	﹤0.01%	3565
2017 Q1	$55K	Buy	+6,075	New	+$53.4K	﹤0.01%	2335
2016 Q1	–	Sell	-8,107	Closed	-$95.2K	–	7946
2015 Q4	$182K	Buy	+8,107	New	+$166K	0.01%	1264

Other funds holding OMED

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return

Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return

Candriam SCA Strassen, Luxembourg, Luxembourg $19.3B AUM 39.18% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Cannell & Co New York $3.15B AUM 30.62% 1-Year Est. Return

Cutler Group's OMED Position: Q2 2018 in Review

Cutler Group sold out of OncoMed Pharmaceuticals, Inc. (OMED) in Q2 2018, closing a stake of 856 shares — an estimated $2K sold.

Cutler Group first reported a position in OMED in Q4 2015 and held it in 6 quarters. The position peaked at $182K in Q4 2015. 63 funds tracked by Wall St. Rank hold OMED as of Q2 2018.

Cutler Group reported no remaining OncoMed Pharmaceuticals, Inc. position as of Q2 2018 after selling out during the quarter.
Cutler Group sold 856 OncoMed Pharmaceuticals, Inc. shares in Q2 2018, an estimated $2K.
Cutler Group first reported a position in OncoMed Pharmaceuticals, Inc. in Q4 2015 and held it in 6 quarters.
Cutler Group's OncoMed Pharmaceuticals, Inc. position peaked at $182K in Q4 2015.
63 funds tracked by Wall St. Rank held OncoMed Pharmaceuticals, Inc. as of Q2 2018.

Based on Cutler Group's 13F filing for Q2 2018, filed 10 Aug 2018.